TICKERNERD
Menu
PCRXPCRXHealthcare · Drug Manufacturers - Specialty & Generic

PCRX Stock Forecast: Pacira Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$25
+0.79% on the day

The 7 Wall Street analysts covering Pacira Biosciences, Inc. hold a median 12-month price target of $30 — +18.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.0B
Ticker Nerd rank
99 / 100
Median analyst target
$30
Analysts covering
7
Revenue$192.4M+6.2% y/y
Operating income$11.9M
Net income$4.7M
Free cash flow$56.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.7%
1M
+4.0%
YTD
−2.0%
1Y
−6.2%
From 52W high
−8.2%
From 52W low
+32.4%
$19
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PCRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pacira Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
100
Value
99
Accruals
99
Quality
95
Volatility
92
Growth
78
Momentum
56
Revisions
54
Size
44

Issuance (100): The share count has been shrinking and the company is not leaning on new borrowing.

Revisions (54): Analysts have, on balance, been cutting their forecasts.

Size (44): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PCRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PCRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26PCRXHigh $38Median $30Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
4 Buy2 Hold1 Sell
Low $23Median $30High $38

The green dot is the last close — the median target sits +18.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026Leerink PartnersInitiatesMarket Perform$28
5 Aug 2026NeedhamMaintainsBuy$32 → $33
5 Aug 2026NeedhamMaintainsBuy—
5 Aug 2026RBC CapitalMaintainsSector Perform$24 → $25
5 Aug 2026RBC CapitalMaintainsSector Perform—
1 July 2026HC Wainwright & Co.ReiteratesBuy—
1 July 2026HC Wainwright & Co.ReiteratesBuy$38
1 May 2026NeedhamMaintainsBuy—
1 May 2026RBC CapitalMaintainsSector Perform—
26 Mar 2026BarclaysMaintainsEqual-Weight—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026NeedhamMaintainsBuy—
9 Dec 2025BarclaysInitiatesEqual-Weight—
17 Nov 2025HC Wainwright & Co.AssumesBuy$38
7 Nov 2025Truist SecuritiesMaintainsBuy—
9 May 2025NeedhamMaintainsBuy—
8 Apr 2025HC Wainwright & Co.MaintainsBuy—
8 Apr 2025NeedhamReiteratesBuy—
28 Feb 2025BarclaysMaintainsOverweight—
28 Feb 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PCRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PCRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Pacira Biosciences, Inc. returned −6.2% against +17.5% for the S&P 500, dividends included.

PCRX vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Oct 25Jan 26Apr 26Jul 26PCRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PCRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.3%
Analysts raising
3
Analysts cutting
3
Fundamentals

Pacira Biosciences, Inc. (PCRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
72.5×

Cheaper than 10% of US stocks

Price / sales
1.4×

Cheaper than 63% of US stocks

Price / book
1.5×

Cheaper than 55% of US stocks

EV / EBITDA
9.5×

Cheaper than 40% of US stocks

Growth & margins
Revenue growth (YoY)
6.2%

Higher than 42% of US stocks

Earnings growth (YoY)
6.2%

Higher than 43% of US stocks

Gross margin
77.0%

Higher than 89% of US stocks

Operating margin
6.2%

Higher than 57% of US stocks

Net margin
2.0%

Higher than 52% of US stocks

Returns & dividend
Return on equity
2.0%

Higher than 47% of US stocks

Return on assets
1.5%

Higher than 55% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pacira Biosciences, Inc. (PCRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pacira Biosciences, Inc. has a market value of $1.0B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $746.2M. The latest quarter grew 6.2% year on year.

  • Net income over the same four quarters: $14.6M, a 2.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.35.

  • Free cash flow in the twelve months to 30 June 2026: $179.5M.

  • Pacira Biosciences, Inc. spent $148.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 39.8M.

  • Trailing P/E: 72.5×; forward P/E: 7.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Pacira Biosciences, Inc. employs 825 people — $904K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

PCRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PCRXPacira Biosciences, Inc.$1.0B
99
AMPHAmphastar Pharmaceuticals, Inc.$1.0B
85
HROWHarrow, Inc.$1.3B
47
XERSXeris Biopharma Holdings, Inc.$1.4B
81
PAHCPhibro Animal Health Corp.$1.4B
93
COLLCollegium Pharmaceutical, Inc.$719.1M
74
ANIPANI Pharmaceuticals, Inc.$1.6B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pacira Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PCRX news & analysis

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 9 Sept 2026neutral

Pacira BioSciences announced that on September 2, 2026 it granted inducement awards to five new employees under its Amended and Restated 2014 Inducement Plan, serving as a material inducement for each employee's entry into employment with the company.

Why it matters — PCRX watchers would care because the inducement grants signal the company's steps to attract and onboard new personnel under its equity compensation plan.

Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 3 Sept 2026neutral

Pacira Biosciences reported earnings 30 days ago, and its stock has risen 6.9% since that report. The article examines what may come next for the company's shares following this post-earnings gain.

Why it matters — A PCRX watcher would care because the piece assesses the stock's trajectory after its most recent earnings report, offering insight into what may lie ahead.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 7 Aug 2026neutral

Pacira BioSciences granted inducement awards to five new employees on August 4, 2026 under its Amended and Restated 2014 Inducement Plan, approved by the People & Compensation Committee without stockholder approval in line with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The grants signal Pacira is hiring and using stock-based incentives to attract new talent, which may be of interest to shareholders tracking company growth and compensation practices.

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

GlobeNewsWire · 6 Aug 2026positive

Pacira BioSciences announced the publication of positive two-year Phase 1 data for PCRX-201 in the Annals of the Rheumatic Diseases. The data showed that a single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis.

Why it matters — A PCRX watcher would care because this publication provides longer-term Phase 1 safety data on PCRX-201, a key candidate in the company's pipeline for treating knee osteoarthritis.

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Zacks Investment Research · 5 Aug 2026neutral

Pacira (PCRX) beat Q2 earnings estimates, with higher product sales boosting revenues as Exparel demand and portfolio momentum supported growth. However, the company cut its 2026 sales outlook.

Why it matters — A PCRX watcher would care because the earnings beat is a positive signal, but the reduced 2026 sales outlook highlights caution about the company's forward growth prospects.

FAQ

Frequently asked questions about PCRX stock

What is the PCRX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Pacira Biosciences, Inc. have a median 12-month price target of $30, with estimates ranging from $23 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PCRX stock a buy right now?

Of the 7 analysts covering Pacira Biosciences, Inc., 4 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pacira Biosciences, Inc. 99 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PCRX?

As at 12 Sept 2026, Pacira Biosciences, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (100 of 100).

Will PCRX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +18.3% from the last close, and Ticker Nerd's factor model ranks Pacira Biosciences, Inc. 99 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PCRX stock forecast for 2030?

No analyst covering Pacira Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $38 over the next 12 months.

How has PCRX stock performed over the past year?

Pacira Biosciences, Inc. returned -6.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pacira Biosciences, Inc. do?

Pacira BioSciences, Inc. is a specialty biopharmaceutical company focused on non-opioid pain management and regenerative health solutions.

What is the latest news on PCRX?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Pacira BioSciences announced that on September 2, 2026 it granted inducement awards to five new employees under its Amended and Restated 2014 Inducement Plan, serving as a material inducement for each employee's entry into employment with the company.

Company

About Pacira Biosciences, Inc.

Pacira BioSciences, Inc. is a specialty biopharmaceutical company focused on non-opioid pain management and regenerative health solutions. Pacira BioSciences develops, manufactures, markets, distributes, and sells therapies used across postsurgical, chronic, and musculoskeletal pain settings, serving healthcare practitioners in the United States. Its commercial portfolio includes EXPAREL, a long-acting local anesthetic used in surgical pain control, ZILRETTA, an extended-release injectable treatment for knee osteoarthritis pain, and iovera°, a handheld device that delivers targeted cold therapy for drug-free pain relief. The company also advances pipeline programs such as PCRX-201, a locally administered gene therapy candidate being studied for osteoarthritis of the knee. Pacira BioSciences plays a notable role in the pain-treatment market by offering alternatives designed to reduce reliance on opioids while supporting patient recovery and function.

CEO Mr. Frank D. Lee · 825 employees · United States · https://www.pacira.com